Protagonist Therapeutics (PTGX) Receivables (2017 - 2026)
Protagonist Therapeutics (PTGX) posted Receivables of $57.1 million for Q1 2026, up 1173.34% sequentially from $4.5 million in Q4 2025.
Protagonist Therapeutics (PTGX) Receivables (2017 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Receivables for 10 years, with the latest figure at $57.1 million in Q1 2026.
- Quarterly Receivables changed N/A year-over-year to $57.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.1 million (changed N/A YoY) and the FY2025 annual result came in at $4.5 million, down 97.33% from the prior year.
- Receivables improved to $57.1 million in Q1 2026 per PTGX's latest filing, from $4.5 million in the prior quarter.
- Over five years, Receivables peaked at $168.2 million in Q4 2024 and troughed at $52000.0 in Q4 2022.
- A 5-year average of $26.2 million and a median of $2.6 million in 2022 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2023: Receivables surged 220.65% in 2022, then sank 99.6% in 2023.
- Over 5 years, Receivables stood at $52000.0 in 2022, then jumped by 50.0% to $78000.0 in 2023, then surged by 215594.87% to $168.2 million in 2024, then plunged by 97.33% to $4.5 million in 2025, then surged by 1173.34% to $57.1 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $57.1 million, $4.5 million, and $5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 16.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.78 Mn |
| Mar 31, 2026 | 57.12 Mn |
| Dec 31, 2025 | 4.49 Mn |
| Sep 30, 2025 | 5.13 Mn |
| Dec 31, 2024 | 168.24 Mn |
| Jun 30, 2023 | 78,000.00 |
| Mar 31, 2023 | 102,000.00 |
| Dec 31, 2022 | 52,000.00 |
| Sep 30, 2022 | 620,000.00 |
| Jun 30, 2022 | 715,000.00 |
| Mar 31, 2022 | 25.63 Mn |
| Dec 31, 2021 | 3.13 Mn |
| Sep 30, 2021 | 5.28 Mn |
| Jun 30, 2021 | 14.15 Mn |
| Mar 31, 2021 | 7.99 Mn |
| Dec 31, 2020 | 4.85 Mn |
| Sep 30, 2020 | 5.58 Mn |
| Jun 30, 2020 | 5.99 Mn |
| Mar 31, 2020 | 3.59 Mn |
| Dec 31, 2019 | 6.76 Mn |